CHEMM · CHEMOMETEC A/S · Investor Relations

ANNOUNCEMENT NO. 317 5 October 2026 ChemoMetec maintained its positive momentum in the first quarter of the 2026/27 financial year, supported by higher-than-expected demand for our instruments, with the NC-203 being a key driver, including a lower-than-expected cost base.

ANNOUNCEMENT NO. 316 2 October 2026 ChemoMetec A/S has completed the share buyback programme announced in company announcement no. 309 dated 15 May 2026. The programme provided for the repurchase of up to 500,000 shares for a total consideration of up to DKK 100 million.

16 September 2026 ANNOUNCEMENT NO. 315 Major shareholder announcement - BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock, Inc., on 14 September 2026, increased its total holding in

Notice of Annual General Meeting 2026 ANNOUNCEMENT NO. 314 16 September 2026 Notice of Annual General Meeting Notice is hereby given of the Annual General Meeting, which will be held on Thursday 8 October 2026 at 5.30 p.m. The general meeting will be held at Nordsjællands KonferenceCenter, Gydevang

ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties’ solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today entered a

ChemoMetec A/S announces its Annual Report for the financial year 2025/26 on Thursday, 10 September, 2026. Following the announcement ChemoMetec A/S will host a conference call on Friday, 11 September, 2026, at 3:00 p.m. CEST. CEO Martin Helbo Behrens and CFO Phillip Massie Price will present the

ANNOUNCEMENT NO. 310 1 August 2026 Appointment of new CFO The board of ChemoMetec has appointed Phillip Massie Price as the new CFO with effect from 3 August 2026. Phillip Massie Price joins ChemoMetec from a position as Director, Corporate Finance at Unimed, a global healthcare group.

ANNOUNCEMENT NO. 309 15 May 2026 Initiation of buy-back programme The Board of Directors of ChemoMetec A/S has decided to buy back own shares based on the authorisation granted at the Annual General Meeting on 9 October 2025. The authorisation is valid until the next Annual General Meeting,

Trading statement for Q3 2025/26 (1 January – 31 March 2026) Growth in revenue and operating profit ChemoMetec’s revenue was up by 15% in the third quarter of 2025/26 to DKK 142.3 million from DKK 124.2 million in the year-earlier period. In local currencies, the revenue growth was 21%.